incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Company profile
Ticker
INCY
Exchange
Website
CEO
Herve Hoppenot
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Zymergen • OmniAb • SomaLogic ...
Former names
INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Incyte Biosciences Corporation • Incyte Holdings Corporation • Incyte Research Institute LLC • Villaris Therapeutics Inc. • Incyte International Holdings Corporation • Incyte Biosciences Canada Corporation • Incyte International Holdings • Incyte Biosciences International • Incyte Biosciences Austria GmbH • Incyte Biosciences Denmark ApS ...
IRS number
943136539
INCY stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
16 Feb 24
S-8
Registration of securities for employees
13 Feb 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Provides 2024 Financial Guidance and Highlights R&D Priorities
13 Feb 24
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates
31 Oct 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates
1 Aug 23
S-8
Registration of securities for employees
30 Jun 23
Transcripts
INCY
Earnings call transcript
2023 Q4
13 Feb 24
INCY
Earnings call transcript
2023 Q3
31 Oct 23
INCY
Earnings call transcript
2023 Q2
31 Jul 23
INCY
Earnings call transcript
2023 Q1
2 May 23
INCY
Earnings call transcript
2022 Q4
7 Feb 23
INCY
Earnings call transcript
2022 Q3
1 Nov 22
INCY
Earnings call transcript
2022 Q2
2 Aug 22
INCY
Earnings call transcript
2022 Q1
3 May 22
INCY
Earnings call transcript
2021 Q4
8 Feb 22
INCY
Earnings call transcript
2021 Q3
2 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
92.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 513 |
Opened positions | 54 |
Closed positions | 53 |
Increased positions | 239 |
Reduced positions | 157 |
13F shares | Current |
---|---|
Total value | 12.02 tn |
Total shares | 208.63 mm |
Total puts | 362.40 k |
Total calls | 485.33 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 36.18 mm | $2.09 tn |
BLK Blackrock | 24.25 mm | $1.40 tn |
Vanguard | 22.16 mm | $1.28 tn |
Dodge & Cox | 16.42 mm | $948.36 bn |
STT State Street | 9.51 mm | $549.45 bn |
Renaissance Technologies | 4.80 mm | $277.30 bn |
Geode Capital Management | 4.17 mm | $240.26 bn |
IVZ Invesco | 3.92 mm | $226.58 bn |
Acadian Asset Management | 2.68 mm | $155.20 bn |
BLVGF Bellevue | 2.49 mm | $143.93 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Baker Bros. Advisors | Common Stock | Grant | Acquire A | Yes | No | 0 | 543 | 0.00 | 33,447,981 |
28 Mar 24 | Baker Bros. Advisors | Common Stock | Grant | Acquire A | Yes | No | 0 | 543 | 0.00 | 2,970,073 |
28 Mar 24 | Clancy Paul J | Common Stock | Grant | Acquire A | No | Yes | 56.97 | 403 | 22.96 k | 15,785 |
28 Mar 24 | Harrigan Edmund | Common Stock | Grant | Acquire A | No | Yes | 56.97 | 413 | 23.53 k | 13,115 |
25 Mar 24 | Matteo Trotta | Common Stock | Grant | Acquire A | No | No | 0 | 7,828 | 0.00 | 7,828 |
25 Mar 24 | Matteo Trotta | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 57.48 | 21,868 | 1.26 mm | 21,868 |
News
China Medical System Announced Collaboration And License Agreement With Incyte For Selective Oral Smallmolecule JAK1 Inhibitor Povorcitinib
1 Apr 24
RBC Capital Reiterates Sector Perform on Incyte, Maintains $65 Price Target
25 Mar 24
B of A Securities Maintains Neutral on Incyte, Lowers Price Target to $67
13 Mar 24
Stifel Reiterates Hold on Incyte, Maintains $68 Price Target
12 Mar 24
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
12 Mar 24
Press releases
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Mar 24
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
10 Mar 24
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
10 Mar 24
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
4 Mar 24
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
29 Feb 24